DBV Technologies completed a $30 million at‑the‑market issuance, selling 2,142,860 American Depositary Shares at $14.00 each. The transaction delivers 10,714,300 ordinary shares, representing 6.34 % of the company’s existing share base and creating a dilution of 5.96 %.
The ATM program was established on September 5, 2025, and the new ordinary shares were delivered on October 31, 2025. This tranche follows earlier issuances on October 6 and October 13, 2025, which raised similar amounts under the same program.
Prior to the financing, DBV reported a net loss of $102.1 million for the nine months ended September 30, 2025, compared with $90.9 million for the same period in 2024. Cash and cash equivalents stood at $69.8 million versus $32.5 million at the end of 2024, and operating expenses were $107.0 million versus $96.4 million, reflecting increased R&D and regulatory costs. The new capital extends the company’s cash runway to the end of the fourth quarter of 2026, providing at least 12 months of liquidity.
The proceeds will support the Viaskin Peanut patch program for toddlers and children, including the Phase 3 VITESSE study and upcoming Biologics License Application filings. The financing also removes substantial doubt about the company’s ability to continue as a going concern, a key milestone for a clinical‑stage biopharmaceutical firm.
DBV operates in a competitive food‑allergy treatment market, with rivals such as Aimmune Bio. The company’s prior ATM issuances have led to cumulative dilution, and this tranche adds 5.96 % dilution. In May 2024, DBV changed its ADS ratio from one ADS per half ordinary share to one ADS per ordinary share to maintain Nasdaq compliance.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.